Alkermes News
Most Popular Alkermes Story
UPDATED: FDA (finally) stamps an approval on Amylin's Bydureon
After being rejected twice by regulatory officials, Amylin has finally won FDA approval to sell Bydureon, its once-weekly diabetes jab. The news sent Amylin's shares up 16% while Alkermes ($ALKS), Read more...
Latest Headlines
- January 27, 2012
- October 25, 2011
- October 19, 2011
- July 27, 2011
- July 19, 2011
- October 11, 2010
- March 10, 2010
- December 4, 2009
- April 22, 2009
- April 7, 2009
- March 19, 2008
- March 11, 2008
- March 7, 2008
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
